{"Symbol": "MYOS", "AssetType": "Common Stock", "Name": "MYOS RENS Technology Inc", "Description": "MYOS RENS Technology Inc. focuses on the discovery, development, and commercialization of nutritional ingredients, functional foods, and other technologies that enhance muscle health and performance. The company primarily focuses on developing Fortetropin for the therapeutic markets, including the treatment of sarcopenia, cachexia, anorexia, obesity, and muscular disorders. Its products include Qurr line of products to support muscle well-being and fitness; Yolked line of products for collegiate and professional athletes; and Myos Canine Muscle Formula line of products for pets. The company sells its products through direct-to-consumer e-commerce platform. It has a research agreement with the University of California to study the effects Of Fortetropin on skeletal muscle protein synthetic rate in older men and women; Rutgers University for the discovery of compounds and products that improve muscle health and performance; Weill Cornell Medical College to study the efficacy of Fortetropin in preventing weight and muscle loss associated with cancer; and McMaster University to study impact of Fortetropin on muscle disuse atrophy in young men. The company was formerly known as MYOS Corporation and changed its name to MYOS RENS Technology Inc. in March 2016. MYOS RENS Technology Inc. was founded in 2007 and is based in Cedar Knolls, New Jersey.", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "Healthcare", "Industry": "Drug ManufacturersSpecialty & Generic", "Address": "45 Horsehill Road, Cedar Knolls, NJ, United States, 07927", "FullTimeEmployees": "15", "FiscalYearEnd": "December", "LatestQuarter": "2020-06-30", "MarketCapitalization": "15874712", "EBITDA": "-3768000", "PERatio": "None", "PEGRatio": "0", "BookValue": "0.239", "DividendPerShare": "None", "DividendYield": "0", "EPS": "-0.377", "RevenuePerShareTTM": "0.142", "ProfitMargin": "-2.7782", "OperatingMarginTTM": "-2.7493", "ReturnOnAssetsTTM": "-0.5392", "ReturnOnEquityTTM": "-1.2315", "RevenueTTM": "1348000", "GrossProfitTTM": "635000", "DilutedEPSTTM": "-0.394", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "1.136", "AnalystTargetPrice": "3.75", "TrailingPE": "0", "ForwardPE": "0", "PriceToSalesRatioTTM": "9.3021", "PriceToBookRatio": "5.5296", "EVToRevenue": "11.4516", "EVToEBITDA": "0", "Beta": "1.0984", "52WeekHigh": "2.42", "52WeekLow": "0.7412", "50DayMovingAverage": "1.4108", "200DayMovingAverage": "1.1436", "SharesOutstanding": "11846800", "SharesFloat": "6304390", "SharesShort": "43224", "SharesShortPriorMonth": "71068", "ShortRatio": "0.04", "ShortPercentOutstanding": "0.01", "ShortPercentFloat": "0.024", "PercentInsiders": "50.083", "PercentInstitutions": "5.831", "ForwardAnnualDividendRate": "0", "ForwardAnnualDividendYield": "0", "PayoutRatio": "0", "DividendDate": "None", "ExDividendDate": "None", "LastSplitFactor": "1:50", "LastSplitDate": "2014-02-10"}